Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study

doi:10.3748/wjg.v21.i46.13087

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 46

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7671)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

685

WORD

296

HTML

3217

Figures (1-5)

192

Tables (1-2)

209

Sum=4599

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1225

Download

1847

Sum=3072

Dec 14, 2015 (publication date) through Jul 28, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Dec 14, 2015; 21(46): 13087-13094
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13087

Full Size Figure Download Figure

Figure 5 Comparison of death rates between the lamivudine and control group. LAM: Lamivudine.

Citation: Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol 2015; 21(46): 13087-13094
URL: https://www.wjgnet.com/1007-9327/full/v21/i46/13087.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i46.13087